Innovations for Emphysema
The Pulmonx portfolio of diagnostics and therapeutics for emphysema enables physicians to successfuly predict outcomes and provide optimal treatment for each individual patient.
We now have the technology to transform patients’ lives.“
You can really change a patient’s life when you apply these therapies.“
Diagnostics
StratX® Lung Analysis Platform:
StratX is a cloud-based quantitative CT analysis service that supports Zephyr® valve patient selection and treatment targeting by providing clinically-validated information on emphysema destruction, fissure completeness and volume.
Chartis® System:
The Chartis System is a pulmonary assessment tool used prior to the Zephyr EBV procedure to identify those patients with low or no collateral ventilation, who are proven to be the most likely to respond to the treatment.
Therapies
Zephyr® Endobronchial Valve:
The Zephyr device is a one-way valve designed to reduce hyperinflation of the lungs caused by emphysema that has been proven in over a decade of clinical experience to significantly improve the lung function, exercise tolerance and quality of life for
patients receiving treatment.
In a minimally invasive procedure, tiny, one-way valves are placed in the lungs to occlude airways in diseased regions and achieve lung volume reduction. As a result, the remaining healthy regions may function more efficiently,
enabling better breathing and an improved quality of life for patients1,2,3. The Zephyr Endobronchial Valve is removable, preserving future therapy options.
AeriSeal® System:
AeriSeal treatment is under limited launch and uses a polymeric foam to block diseased regions in the lung to achieve volume reduction and improve breathing function.
Hear what physicians think about Pulmonx solutions
References
- Herth F. et al. Respiration. 2016 ; DOI: 10.1159/000444090.
- Klooster K. et al. N Engl J Med. 2015; 373: 2325-36 + Supplementary Appendix.
- Davey C. et al. Lancet. 2015; 386(9998):1066-1073.